Search results for "Retina – medical therapies"

showing 2 items of 2 documents

What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects

2020

Within the COVID-19 pandemic context, the WHO has proposed a list of medicines to treat patients with severe acute respiratory syndrome (SARS-CoV-2). An analysis of their ocular side effects was performed. Only chloroquine and hydroxychloroquine were found to have an ocular impact in the medium and long-term. Detailed search strategies were performed in EMBASE, MEDLINE, SCOPUS and WOS Core Collection. Additionally, the worldwide ongoing clinical trials including chloroquine or hydroxychloroquine were evaluated, and their proposals of drug administration and exclusion criteria analyzed. In general, high maximum cumulative doses of chloroquine or hydroxychloroquine are being used for a short…

0301 basic medicinemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsCoronavirus disease 2019 (COVID-19)Health PersonnelRetinal pathology / researchSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Context (language use)medicine.disease_causeRetinaAntimalarials03 medical and health sciences0302 clinical medicineRetinal DiseasesChloroquineInternal medicinePandemicmedicineHumansRETINARetina – medical therapiesCoronavirusPharmacologyOphthalmologistsSARS-CoV-2business.industryCOVID-19ChloroquineHydroxychloroquineGeneral MedicineSystemic drug retinal ToxicityTechniques of retinal examinationCOVID-19 Drug TreatmentCoronavirusClinical trialOphthalmology030104 developmental biologyCaregiversMedicina Preventiva y Salud Pública030221 ophthalmology & optometryHuman medicinebusinessHydroxychloroquinemedicine.drugEuropean journal of ophthalmology
researchProduct

Treat and extend versus fixed regimen in neovascular age related macular degeneration: A systematic review and meta-analysis

2020

Purpose: To compare efficacy of treat and extend (T&E) versus fixed regimen treatment protocols in neovascular age-related macular degeneration (nAMD). Methods: Randomized clinical trials (RCTs) comparing T&E versus fixed regimen protocols for nAMD were systematically searched. Primary outcome was to compare the mean best corrected visual acuity (BCVA) change in T&E regimen versus fixed regimen. Secondary outcomes were change in the mean optical coherence tomography (OCT) central retinal thickness (CRT) and mean number of injections. Standardized mean difference (SMD) along with 95% confidence intervals (CIs) were calculated. Random-effect models were used for meta-analyses. Res…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyretinaretinal pathology/researchVisual AcuityAngiogenesis InhibitorsTreat and extendlaw.inventionMacular DegenerationRandomized controlled trialClinical Protocolsretina – medical therapieslawInternal medicineAge relatedRanibizumabMedicineHumansbusiness.industryAge-related macular degenerationGeneral MedicineMacular degenerationpediatric ophthalmologyretina – medical therapiemedicine.diseaseOphthalmologyRegimenTreatment OutcomeMeta-analysisvitreous/retinal diseaseIntravitreal InjectionsWet Macular DegenerationPediatric ophthalmologypharmacologybusinessTomography Optical CoherenceAge-related macular degeneration; pediatric ophthalmology; pharmacology; retina; retina – medical therapies; retinal pathology/research; vitreous/retinal disease
researchProduct